Nanocarriers Market Report 2026

Nanocarriers Market Report 2026
Global Outlook – By Type (Polymeric Nanocarriers, Lipid-Based Nanocarriers, Inorganic Nanocarriers, Other Types), By Application (Drug Delivery, Diagnostics, Vaccines, Gene Therapy, Other Applications), By End-User (Pharmaceutical And Biotechnology Companies, Hospitals And Clinics, Research Institutes, Other End-Users) – Market Size, Trends, Strategies, and Forecast to 2035
Nanocarriers Market Overview
• Nanocarriers market size has reached to $11.61 billion in 2025 • Expected to grow to $26.74 billion in 2030 at a compound annual growth rate (CAGR) of 18.1% • Growth Driver: Rise In Demand For Personalized Medicines Driving The Growth Of The Market Due To Targeted And Patient-Specific Drug Delivery • Market Trend: Advancements In Lipid Nanoparticle Manufacturing For Targeted Therapeutics • North America was the largest region in 2025.What Is Covered Under Nanocarriers Market?
Nanocarriers refer to nanoscale delivery systems that are specifically engineered to carry drugs, genes, or other therapeutic agents with high precision, ensuring they reach the intended cells or tissues in the body. These advanced carriers improve the stability and bioavailability of therapeutic compounds, allow for controlled and sustained release, and help minimize potential side effects by reducing exposure to healthy tissues. The main types of nanocarriers are polymeric nanocarriers, lipid-based nanocarriers, inorganic nanocarriers, and others. Polymeric Nanocarriers are nanoscale polymer-based systems designed to deliver drugs or therapeutic agents efficiently to targeted sites in the body. It is used for applications such as drug delivery, diagnostics, vaccines, gene therapy, and others, serving end-users including pharmaceutical and biotechnology companies, hospitals and clinics, research institutes, and others.
What Is The Nanocarriers Market Size and Share 2026?
The nanocarriers market size has grown rapidly in recent years. It will grow from $11.61 billion in 2025 to $13.74 billion in 2026 at a compound annual growth rate (CAGR) of 18.4%. The growth in the historic period can be attributed to advancements in nanotechnology research, increasing pharmaceutical R&D investments, growing need for improved drug bioavailability, early adoption of nanoparticle-based therapeutics, expansion of academic and clinical research.What Is The Nanocarriers Market Growth Forecast?
The nanocarriers market size is expected to see rapid growth in the next few years. It will grow to $26.74 billion in 2030 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to increasing demand for personalized therapeutics, rising investments in advanced drug delivery systems, expansion of nanocarrier applications in oncology and gene therapy, growing focus on reducing drug side effects, continued innovation in nanoscale engineering. Major trends in the forecast period include increasing development of targeted drug delivery platforms, growing adoption of lipid and polymeric nanocarriers, rising focus on controlled and sustained release systems, expansion of nanocarriers in gene and vaccine delivery, enhanced integration with precision medicine approaches.Global Nanocarriers Market Segmentation
1) By Type: Polymeric Nanocarriers, Lipid-Based Nanocarriers, Inorganic Nanocarriers, Other Types 2) By Application: Drug Delivery, Diagnostics, Vaccines, Gene Therapy, Other Applications 3) By End-User: Pharmaceutical And Biotechnology Companies, Hospitals And Clinics, Research Institutes, Other End-Users Subsegments: 1) By Polymeric Nanocarriers: Nanoparticles Of Poly Lactic Acid, Nanoparticles Of Poly Lactic-Co-Glycolic Acid, Nanoparticles Of Chitosan, Nanoparticles Of Gelatin, Nanoparticles Of Polycaprolactone 2) By Lipid-Based Nanocarriers: Solid Lipid Nanoparticles, Nanostructured Lipid Carriers, Liposomes, Nanoemulsions, Self-Emulsifying Drug Delivery Systems 3) By Inorganic Nanocarriers: Gold Nanoparticles, Silver Nanoparticles, Silica Nanoparticles, Magnetic Nanoparticles, Quantum Dots 4) By Other Types: Dendrimers, Protein-Based Nanocarriers, Carbon Nanotubes, Nanocrystals, ExosomesWhat Is The Driver Of The Nanocarriers Market?
The rise in demand for personalized medicines is expected to propel the growth of the nanocarriers market going forward. Personalized medicine refers to the practice of tailoring medical treatment to the individual characteristics of each patient, particularly by using genetic, biomarker, and molecular information. The emphasis on personalized medicine is growing as it allows doctors to tailor cancer treatments to a patient’s genetic profile, improving effectiveness and reducing unnecessary side effects. Nanocarriers enable personalized medicine deliver drugs precisely to patient-specific targets, controlling release, improving bioavailability, and allowing tailored combination therapies based on individual biological profiles. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the United States Food and Drug Administration (FDA) approved 16 new personalized therapies for patients with rare diseases, marking a sharp increase from just six approvals in 2022. Therefore, the rise in demand for personalized medicines is driving the growth of the nanocarriers industry.Key Players In The Global Nanocarriers Market
Major companies operating in the nanocarriers market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi S.A., Novartis AG, Bristol-Myers Squibb Company, Amgen Inc., Evonik Industries AG, Matinas BioPharma Holdings Inc., Luye Pharma Group Ltd., Ascendia Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Nanobiotix S.A., Polymun Scientific Immunbiologische Forschung GmbH, ReCode Therapeutics Inc., Celsion Corporation, Starpharma Holdings Limited, EnGeneIC Ltd., Acuitas Therapeutics Inc., Altamira Therapeutics Ltd., Nanexa ABGlobal Nanocarriers Market Trends and Insights
Major companies operating in the nanocarriers market are prioritizing the development of advanced formulations, including lipid nanoparticle technologies, to enhance targeted drug delivery and improve therapeutic efficacy. Lipid nanoparticle technologies are nanoscale, fat-based carriers designed to deliver drugs or genetic therapies safely and efficiently to targeted cells or tissues. For instance, in July 2023, Cytiva, a US-based biotechnology company, launched the NanoAssemblr commercial formulation system, a single-use, fully automated platform designed to enable end-to-end clinical and commercial manufacturing of lipid nanoparticle (LNP) medicines. This system uses Cytiva’s NxGen technology to provide controlled, reproducible mixing for consistent quality throughout all stages from research to large-scale manufacturing under cGMP conditions. The platform reduces cross-contamination risk with its single-use fluid path and supports efficient multi-product manufacturing in one facility. It also features intuitive software compliant with regulatory standards that automates workflows and enables electronic batch records, streamlining production of genomic medicines such as mRNA vaccines, gene therapies, and cancer vaccines.What Are Latest Mergers And Acquisitions In The Nanocarriers Market?
In August 2024, VION Biosciences LLC, a US-based life science platform company, acquired Echelon Biosciences Inc. for an undisclosed amount. With this acquisition, VION Biosciences aims to effectively serve customers focused on delivering a variety of mRNA and gene-based biotherapeutics by expanding VION's portfolio, strengthening its drug discovery and preclinical capabilities, and enabling its entry into the drug manufacturing space. Echelon Biosciences Inc. is a US-based biotechnology company that manufactures lipid nanoparticles (LNPs), a type of nanocarrier crucial for delivering mRNA-based therapies.Regional Insights
North America was the largest region in the nanocarriers market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Nanocarriers Market?
The nanocarriers market consists of sales of polymeric nanoparticles, nanocrystals, carbon nanotubes, exosomes, and quantum dots. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Nanocarriers Market Report 2026?
The nanocarriers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nanocarriers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Nanocarriers Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $13.74 billion |
| Revenue Forecast In 2035 | $26.74 billion |
| Growth Rate | CAGR of 18.4% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Type, Application, End-User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi S.A., Novartis AG, Bristol-Myers Squibb Company, Amgen Inc., Evonik Industries AG, Matinas BioPharma Holdings Inc., Luye Pharma Group Ltd., Ascendia Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Nanobiotix S.A., Polymun Scientific Immunbiologische Forschung GmbH, ReCode Therapeutics Inc., Celsion Corporation, Starpharma Holdings Limited, EnGeneIC Ltd., Acuitas Therapeutics Inc., Altamira Therapeutics Ltd., Nanexa AB |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
Frequently Asked Questions
The Nanocarriers market was valued at $11.61 billion in 2025, increased to $13.74 billion in 2026, and is projected to reach $26.74 billion by 2030.
request a sample hereThe global Nanocarriers market is expected to grow at a CAGR of 18.1% from 2026 to 2035 to reach $26.74 billion by 2035.
request a sample hereSome Key Players in the Nanocarriers market Include, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi S.A., Novartis AG, Bristol-Myers Squibb Company, Amgen Inc., Evonik Industries AG, Matinas BioPharma Holdings Inc., Luye Pharma Group Ltd., Ascendia Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Nanobiotix S.A., Polymun Scientific Immunbiologische Forschung GmbH, ReCode Therapeutics Inc., Celsion Corporation, Starpharma Holdings Limited, EnGeneIC Ltd., Acuitas Therapeutics Inc., Altamira Therapeutics Ltd., Nanexa AB .
request a sample hereMajor trend in this market includes: Advancements In Lipid Nanoparticle Manufacturing For Targeted Therapeutics. For further insights on this market.
request a sample hereNorth America was the largest region in the nanocarriers market in 2025. The regions covered in the nanocarriers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
request a sample here